Research Topics
Species | John H AlexanderSummaryAffiliation: Duke University Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Inhibition of Factor Xa : a potential target for the development of new anticoagulantsJohn H Alexander
Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina 27710, USA
Am J Cardiovasc Drugs 5:279-90. 2005..Ongoing investigation with numerous oral and parenteral inhibitors of Factor Xa will establish the potential of Factor Xa as a target for therapeutic anticoagulation...
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trialJohn H Alexander
Duke Clinical Research Institute, Duke University Medical Center, DUMC Box 3850, Durham, NC 27715, USA
Circulation 119:2877-85. 2009..After an acute coronary syndrome, patients remain at risk of recurrent events. Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding...- Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trialJohn H Alexander
Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina 27715, USA
JAMA 299:1777-87. 2008..Phase 2 trial data suggest that MC-1 may reduce death or MI in high-risk patients undergoing CABG surgery... - Apixaban with antiplatelet therapy after acute coronary syndromeJohn H Alexander
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
N Engl J Med 365:699-708. 2011..Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome... - The current state of antiplatelet therapy in acute coronary syndromes: the data and the real worldJohn H Alexander
Duke University Medical Center, Duke Clinical Research Institute, DUMC Box 3850, Durham, NC 27715, USA
Cleve Clin J Med 76:S16-23. 2009..More evidence-based use of existing and emerging antiplatelet agents has the potential to improve both ischemic and bleeding outcomes in patients with ACS... - The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristicsJohn H Alexander
Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27715, USA
Am Heart J 150:643-9. 2005..Edifoligide inhibits E2F, a transcription factor that activates cell-cycle genes responsible for neointimal hyperplasia... - Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trialJohn H Alexander
Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27715, USA
JAMA 294:2446-54. 2005..Edifoligide is an oligonucleotide decoy that binds to and inhibits E2F transcription factors and thus may prevent neointimal hyperplasia and vein graft failure... - Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgeryRenato D Lopes
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
N Engl J Med 361:235-44. 2009.... - Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgeryRenato D Lopes
Duke Clinical Research Institute, Duke University Medical Center, DUMC Box 3850, Durham, NC 27705, USA
Circulation 125:749-56. 2012..In this retrospective analysis, we examined the relationship between VGF, assessed by coronary angiography 12 to 18 months after coronary artery bypass graft surgery, and subsequent clinical outcomes... - Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromesKenneth W Mahaffey
Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
Am J Cardiol 95:1404-8. 2005..All MI types were associated with worse short- and long-term outcomes. Characterization of the type of MI provides an opportunity for more informed interpretation of clinical trial results and improved planning for future trials... - Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patientsConnie N Hess
Duke Clinical Research Institute, Durham, NC 27705, USA
Am Heart J 164:607-15. 2012..Balancing safe and effective use of aspirin, clopidogrel, and warfarin in this population is important... - Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trialsJohn M Galla
Duke Clinical Research Institute, Durham, NC 27705, USA
Am Heart J 151:16-24. 2006..All patients with ACS should have CK-MB measurement to search for cardiac ischemia. Patients with elevated CK-MB should receive aggressive management commensurate with their increased risks... - Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trialRajendra H Mehta
Duke Clinical Research Institute, Box 17969, Durham, NC 27715, USA
Circulation 124:280-8. 2011.... - Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysisRajendra H Mehta
Duke Clinical Research Institute, Durham, North Carolina, USA
Am J Cardiol 109:320-6. 2012..These data highlight the importance of understanding factors associated with gender-related differences in bleeding and represent an opportunity for improving outcomes of women and men with fibrinolytic-treated STEMI... - Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year resultsRenato D Lopes
Duke Clinical Research Institute, Durham, NC, USA
Am Heart J 164:379-386.e1. 2012..We compared the 5-year clinical outcomes of patients in PREVENT IV treated with edifoligide and placebo to identify predictors of long-term clinical outcomes... - Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV)James M Yau
Duke University Medical Center, Durham, North Carolina, USA
Am J Cardiol 102:546-51. 2008..Further research is needed into the prevention and treatment of perioperative MI in patients undergoing CABG... - Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapyTrip J Meine
Division of Cardiology, Department of Medicine, Duke University, Durham, NC 27715, USA
Am Heart J 149:670-4. 2005..We sought to delineate predictors of AVB and determine long-term mortality of patients developing AVB in the setting of ST-segment elevation MI (STEMI) treated with thrombolytic therapy... - Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgeryRajendra H Mehta
Duke Clinical Research Institute and Duke University Medical Center, Durham, NC 27715, USA
J Thorac Cardiovasc Surg 136:1149-55. 2008..Limited information exists on the impact of preoperative renal dysfunction on internal thoracic artery and saphenous vein graft failure and 2-year clinical outcomes in patients undergoing coronary artery bypass surgery... - Apixaban versus warfarin in patients with atrial fibrillationChristopher B Granger
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
N Engl J Med 365:981-92. 2011..Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin... - A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass GraftRajendra H Mehta
Duke Clinical Research Institute, Durham, NC 27715, USA
Am Heart J 155:600-8. 2008.... 
Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarctionJonathan P Piccini
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Crit Care Med 39:78-83. 2011..The objective of this analysis was to describe the survival of patients with sustained ventricular tachycardia/ventricular fibrillation after myocardial infarction according to antiarrhythmic drug treatment...- Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndromeRichard C Becker
Division of Cardiology and Hematology, Duke University School of Medicine, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina 27705, USA
Thromb Haemost 104:976-83. 2010..5 mg twice daily dose. The effect on both D-dimer and F 1.2 was apixaban concentration-and factor Xa inhibition dependent, durable and provided general guidance for dose selection in phase 3 investigation... - Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trialRenato D Lopes
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
Lancet 380:1749-58. 2012..We assessed in this trial's participants how results differed according to patients' CHADS(2), CHA(2)DS(2)VASc, and HAS-BLED scores, used to predict the risk of stroke and bleeding... - Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trialsKenneth W Mahaffey
Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA, and Catholic University Hospital, Leuven, Belgium
Eur Heart J 28:425-32. 2007..To assess the significance of creatine kinase (CK)-MB elevations in outcomes of patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) who have undergone coronary artery bypass grafting (CABG) surgery... - Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgeryAbhinav Goyal
Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
Ann Thorac Surg 83:993-1001. 2007..We investigated whether greater use of secondary prevention medications after coronary artery bypass graft surgery is associated with improved clinical outcomes... - Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgeryAbdul R Halabi
Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
Am J Cardiol 96:1254-9. 2005..36, 95% confidence interval 2.00 to 2.79, p <0.0001). In conclusion, in contemporary clinical practice, early SVG failure is associated with worse long-term outcomes after CABG... - Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery diseaseMark Y Chan
Duke Clinical Research Institute, 2400 Pratt St, Terrace Level Room 0311, Durham, NC 27705, USA
Circulation 117:2865-74. 2008..REG1 consists of RB006 (drug), an injectable RNA aptamer that specifically binds and inhibits factor IXa, and RB007 (antidote), the complementary oligonucleotide that neutralizes its anti-IXa activity... - Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic TherapyRajendra H Mehta
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
Am J Med 124:48-57. 2011.... - Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationaleRenato D Lopes
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Am Heart J 159:331-9. 2010.... - Promise of factor Xa inhibition in atrial fibrillationSana M Al-Khatib
Division of Cardiology, Department of Medicine, Duke Clinical Research Institute and Duke University, 2400 Pratt Street, PO Box 17969, Durham, NC 27705, USA
Curr Cardiol Rep 14:70-8. 2012.... - Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudyThomas J Povsic
Department of Medicine, Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Box 103208, Durham, NC 27710, USA
Eur Heart J 32:2412-9. 2011..The REG1 system (Regado Biosciences, Basking Ridge, NJ) consists of pegnivacogin (RB006), an RNA aptamer that directly inhibits factor IXa, and anivamersen (RB007), its complementary control agent... - Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) TrialSana M Al-Khatib
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Am Heart J 158:792-8. 2009..Current practice related to the management of atrial fibrillation (AF) complicating coronary artery bypass grafting (CABG) is uncertain... - Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapyRajendra H Mehta
Duke Clinical Research Institute, Durham, North Carolina, USA
Am J Cardiol 95:1371-5. 2005..962 (95% CI 0.896 to 1.033). These data indicate that height-related differences in 30-day mortality are explained in large part by height-related differences in patients' clinical characteristics... - Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, BrazilRenato D Lopes
Duke Clinical Research Institute, Duke University Medical Center, Box 3850, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA
J Thromb Thrombolysis 32:242-66. 2011..This paper summarizes the symposium proceedings... - Association between endoscopic vs open vein-graft harvesting and mortality, wound complications, and cardiovascular events in patients undergoing CABG surgeryJudson B Williams
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
JAMA 308:475-84. 2012..The safety and durability of endoscopic vein graft harvest in coronary artery bypass graft (CABG) surgery has recently been called into question... - Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitorRichard C Becker
Division of Cardiology, Duke University School of Medicine, Duke University Medical Center, Duke Clinical Research Institute, Advanced Biomarker Program, 2400 Pratt Street, Durham, NC 27705, USA
J Thromb Thrombolysis 32:183-7. 2011..While establishing parameters for safety and efficacy will require further investigation, an ability to discern the presence of a drug effect may provide clinically useful information... - Influence of body mass index on the efficacy of revascularization in patients with coronary artery diseaseAslan T Turer
Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA
J Thorac Cardiovasc Surg 137:1468-74. 2009..We examined the effect of body mass index on the association between revascularization strategy and survival in patients with coronary artery disease... - Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromesAbdallah G Rebeiz
Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27715, USA
Am J Med 116:119-29. 2004..We review the current evidence regarding the optimal integration of early antithrombotic and antiplatelet therapies with early coronary angiography and subsequent revascularization... - Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarctionRichard E Waters
Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
J Am Coll Cardiol 43:2153-9. 2004..Consequently, this current evolution of reperfusion strategies has the potential to further reduce morbidity and mortality for patients presenting with STEMI... - Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomesRajendra H Mehta
Duke Clinical Research Institute and Duke University Medical Center, Durham, NC 27710, USA
JAMA 293:1746-50. 2005..These data highlight the need for caution when ascribing a causal relationship to associations between incorrect dosing and adverse outcomes... - Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinicianConnie N Hess
Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311 Terrace Level, Box 3850, Durham, NC 27705, USA
J Thromb Thrombolysis 34:552-61. 2012..We provide a review of the clinical syndrome and practical summary of treatment recommendations from the most recent 2012 American College of Chest Physicians evidence-based guidelines for the treatment and prevention of HIT... - Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: Validity, pitfalls, and future approachesSumeet Subherwal
Duke Clinical Research Institute, Durham, NC Electronic address
Am Heart J 165:644-654.e1. 2013..We describe alternative statistical approaches for concurrent assessment of the safety and efficacy of antithrombotic therapies used to treat patients with NSTE ACS... - Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitorRichard C Becker
Duke Cardiovascular Thrombosis Center, Duke University Medical Center, Durham, NC 27705, USA
J Thromb Thrombolysis 18:193-7. 2004.... - Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) TrialSunil V Rao
Duke Clinical Research Institute, Durham, NC, USA
Circulation 121:1713-21. 2010..We performed a phase 2 randomized trial to evaluate the safety and feasibility of M118 in the setting of elective percutaneous coronary intervention... - Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trialJohn H Alexander
Duke University, Durham, NC, USA
JAMA 297:1657-66. 2007..Preliminary, single-center studies suggested a beneficial effect of NOS inhibition on hemodynamics, renal function, and survival in patients with cardiogenic shock... - Incremental prognostic power of single-photon emission computed tomographic myocardial perfusion imaging in patients with known or suspected coronary artery diseaseSalvador Borges-Neto
Department of Medicine Cardiology, Duke University Medical Center, Durham, NC 27710, USA
Am J Cardiol 95:182-8. 2005..This information may be useful for stratifying patients into multiple risk categories for future cardiovascular events and potentially guiding therapy... - The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trialJohn P Vavalle
Duke University Medical Center, Durham, NC 27705, USA
Am Heart J 162:996-1002. 2011..Eptifibatide dosing is weight adjusted for patients up to 121 kg. Patients above this weight receive the same maximal dose, although it is unknown if this provides adequate eptifibatide concentration or platelet inhibition... - Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinicianS Michael Gharacholou
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
J Thromb Thrombolysis 29:516-28. 2010.... - Saphenous vein graft failure and clinical outcomes: Toward a surrogate end point in patients following coronary artery bypass surgery?Ralf E Harskamp
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Am Heart J 165:639-43. 2013..Given the lack of supportive evidence showing a consistent association between SVG failure and major adverse cardiovascular events, SVG failure should not be considered a valid surrogate endpoint at this time... - First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activityChristopher K Dyke
Duke Clinical Research Institute, Durham, NC 27715, USA
Circulation 114:2490-7. 2006..The primary objective was to determine the safety profile and to characterize the pharmacodynamic responses in this first-in-human study... - Novel oral anticoagulants after acute coronary syndromesNewton B Wiggins
Duke University Medical Center, Durham, NC 27715, USA
Cardiovasc Drugs Ther 26:265-71. 2012..This review discusses these agents and their respective clinical trials in patients with acute coronary syndromes... - Design, rationale, and initiation of the Surgical Interventions for Moderate Ischemic Mitral Regurgitation Trial: a report from the Cardiothoracic Surgical Trials NetworkPeter K Smith
Division of Cardiovascular and Thoracic Surgery, Duke University, Durham, NC, USA
J Thorac Cardiovasc Surg 143:111-7, 117.e1. 2012..The optimal treatment of this condition has become increasingly controversial, and a randomized trial evaluating current practices is warranted... - Hand-held echocardiographic examination of patients with symptoms of acute coronary syndromes in the emergency department: the 30-day outcome associated with normal left ventricular wall motionPatrick Weston
Duke Clinical Research Institute, Durham, NC 27705, USA
Am Heart J 148:1096-101. 2004.... - Antithrombotic therapy for ischemic stroke: guidelines translated for the clinicianAnandi Krishnan
Duke Clinical Research Institute, Duke University Medical Center, Box 3850, 27710, Durham, NC, USA
J Thromb Thrombolysis 29:368-77. 2010..Future directions are also reviewed, with particular emphasis on improving therapeutic options early after stroke onset... - Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromesJohn H Alexander
Duke Clinical Research Institute, Durham, North Carolina 27710, USA
Am J Med 115:613-9. 2003..To investigate the prognostic importance of new small Q waves following an acute coronary syndrome... - Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinicianRenato D Lopes
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
J Thromb Thrombolysis 26:167-74. 2008.... - Glycemic management in diabetes and the associated cardiovascular risk: are we helping or hurting our patients?Masaya Koshizaka
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
Circ J 76:1572-80. 2012.... - Feasibility of point-of-care echocardiography by internal medicine house staffJohn H Alexander
Duke University Medical Center, Durham, NC, USA
Am Heart J 147:476-81. 2004..To determine whether internal medicine house staff with limited training in echocardiography can use point-of-care echocardiography to make simple, clinically important diagnoses... - A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarctionThomas J Povsic
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Am Heart J 162:654-662.e1. 2011..We sought to determine the safety and preliminary efficacy of transcatheter intramyocardial administration of myoblasts in patients with heart failure (HF)... - Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directionsRalf E Harskamp
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC Division of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Division of Cardiothoracic Surgery, University of Texas Health Science Center at San Antonio, San Antonio, TX
Ann Surg 257:824-33. 2013..To review our current understanding of the epidemiology and pathogenesis of vein graft failure (VGF), give an overview of current preventive and interventional measures, and explore strategies that may improve vein graft patency... - A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase Thomas J Povsic
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Am Heart J 161:261-268.e1-2. 2011.... - Prophylaxis for venous thromboembolism: guidelines translated for the clinicianGregg Stashenko
Duke Clinical Research Institute, Duke University Medical Center, Box 3850, Durham, NC 27710, USA
J Thromb Thrombolysis 31:122-32. 2011..In addition, we will discuss recent clinical trials regarding novel anticoagulants for venous thromboembolism prophylaxis and share some conclusions... - Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?K Martijn Akkerhuis
Thoraxcenter, University Hospital Rotterdam, The Netherlands
Circulation 105:554-6. 2002.... - Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudyVictor L Serebruany
Sinai Hospital, Johns Hopkins University, Baltimore, MD, USA
Am Heart J 145:636-42. 2003..Therefore, the success of fibrinolytic therapy may be dependent on its direct effects on platelets... - Screening for structural heart disease: time to stop listening and start lookingJohn H Alexander
Am Heart J 146:570-1. 2003 - Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trialMarc Cohen
Division of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Ave, Newark, NJ 07112, USA
Circulation 115:2642-51. 2007..Otamixaban, a selective and direct inhibitor of factor Xa, was investigated in patients undergoing nonurgent percutaneous coronary intervention... - Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarctionPeter R Sinnaeve
Department of Cardiology, University of Leuven, Leuven, Belgium
Am Heart J 147:993-8. 2004..Despite a reduction in ischemic complications after acute myocardial infarction with the use of full-dose tenecteplase plus enoxaparin or half-dose tenecteplase plus abciximab, mortality at 1 year was similar in these treatment groups... - Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 TrialsJohn H Alexander
Curr Cardiol Rep 8:279-81. 2006 - Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IVMitchell J Magee
Cardiopulmonary Research Science and Technology Institute, Dallas, Texas, USA
Ann Thorac Surg 85:494-9; discussion 499-500. 2008.... - Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3)Jeptha P Curtis
Yale University School of Medicine, New Haven, Connecticut, USA
Am J Cardiol 94:279-83. 2004..49, 95% CI 0.35 to 0.67) than did patients in ASSENT-2. These findings support the use of smaller dose, weight-adjusted heparin in patients with ST-elevation myocardial infarction treated with tenecteplase... - Impact of saphenous vein graft radiographic markers on clinical events and angiographic parametersStephen A Olenchock
Cardiothoracic Surgery Department, Tufts University School of Medicine and Caritas St Elizabeth s Medical Center, Boston, Massachusetts, USA
Ann Thorac Surg 85:520-4. 2008..The goal of the present analysis was to evaluate the association of SVG markers with clinical outcomes and graft patency... - Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction: the ASSENT-2 troponin substudyLene H Madsen
Department of Cardiology and Endocrinology, Frederiksberg University Hospital, Copenhagen, Denmark
Circ Res 99:1141-7. 2006..Infarct size and time to initiation of treatment was the major determinant for degradation... - Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging studyVladimir Dzavik
University Health Network, Toronto General Hospital, 6 246, 200 Elizabeth Street, Toronto M5G 2C4, Ontario, Canada
Eur Heart J 28:1109-16. 2007..We assessed preliminary efficacy and safety of four doses of l-n-monomethyl-arginine (l-NMMA), a non-selective NOS inhibitor, in patients with AMI complicated by CS despite an open infarct-related artery...